PDS Biotechnology (NASDAQ:PDSB) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a report released on Saturday morning.

A number of other research firms also recently commented on PDSB. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a report on Wednesday, April 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Trading Down 2.7%

Shares of PDSB stock opened at $0.68 on Friday. The firm’s 50-day simple moving average is $0.94 and its 200-day simple moving average is $0.89. The company has a debt-to-equity ratio of 2.73, a current ratio of 2.26 and a quick ratio of 2.26. PDS Biotechnology has a 1-year low of $0.51 and a 1-year high of $1.55. The firm has a market cap of $38.10 million, a P/E ratio of -1.02 and a beta of 1.59.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. As a group, equities analysts forecast that PDS Biotechnology will post -0.52 EPS for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors have recently bought and sold shares of the business. Armistice Capital LLC purchased a new stake in PDS Biotechnology during the 4th quarter worth $2,182,000. Squarepoint Ops LLC lifted its holdings in PDS Biotechnology by 116.1% in the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after buying an additional 156,662 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after buying an additional 106,300 shares during the last quarter. Susquehanna International Group LLP boosted its position in PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after buying an additional 80,937 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in PDS Biotechnology in the 2nd quarter valued at about $92,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.